Etavopivat
- Generic Name
- Etavopivat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O6S
- CAS Number
- 2245053-57-8
- Unique Ingredient Identifier
- V4E0A9M44Q
- Background
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
- Associated Conditions
- -
- Associated Therapies
- -
A Research Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 408
- Registration Number
- NCT06612268
- Locations
- ๐บ๐ธ
Stanford University_Palo Alto, Palo Alto, California, United States
๐บ๐ธHenry Ford Hospital_Detroit, Detroit, Michigan, United States
๐จ๐ฆUHN-Toronto General Hospital, Toronto, Ontario, Canada
A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT06581627
- Locations
- ๐จ๐ณ
Beijing Hospital, Beijing, Beijing, China
A Research Study of the Effect of Food on Etavopivat in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT06433661
- Locations
- ๐บ๐ธ
ICON-Salt Lake City, Salt Lake City, Utah, United States
A Research Study on Etavopivat in Participants With and Without Liver Disease
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT06336018
- Locations
- ๐บ๐ธ
Amer. Rrsch Corp-TX Liver Inst, San Antonio, Texas, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06198712
- Locations
- ๐ฐ๐ช
Ahero Clinical Trials Unit, Kisumu, Kenya, Kisumu, Kenya
๐ฐ๐ชKombewa Clinical Research Centre, Kisumu, Kenya
๐ฑ๐งAmerican University of Beirut Medical center, Beirut, Lebanon
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05953584
- Locations
- ๐ฎ๐ณ
All India Institute of Medical Sciences (AIIMS), Raipur, Raipur, Chhattisgarh, India
๐ฎ๐ณAll India Institute of Medical Sciences-Delhi, Delhi, India
๐ฎ๐ณNirmal Hospital Pvt. Ltd., Gujarat, India
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05725902
- Locations
- ๐บ๐ธ
Emory University Children's Healthcare of Atlanta, Atlanta, Georgia, United States
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05568225
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Plainsboro, New Jersey, United States
๐บ๐ธNorthwell Health, Plainsboro, New Jersey, United States
๐บ๐ธNorthwestern Memorial Hospital, Plainsboro, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.